
Abeona Therapeutics (ABEO) Stock Forecast & Price Target
Abeona Therapeutics (ABEO) Analyst Ratings
Bulls say
Abeona Therapeutics Inc is projected to generate approximately $32 million in top-line revenue for 2025, with significant growth expected to reach $130.4 million in 2026, indicating strong revenue potential as the company advances its clinical programs. The favorable market access situation is anticipated to steadily improve, suggesting that the company's products may increasingly gain coverage and acceptance within the healthcare system. Additionally, the company's diverse pipeline assets in gene therapies and plasma-based products are expected to contribute positively to financial forecasts, driving potential upside in future performance.
Bears say
Abeona Therapeutics Inc. faces significant risks that contribute to a negative outlook on its stock, primarily centered around the commercial viability of its lead product, pz-cel. There are concerns regarding slower-than-expected adoption of pz-cel in the U.S. market, as well as challenges related to maximizing its value outside the United States. Additionally, potential setbacks in the company's earlier-stage pipeline programs and the risk of long-term dilution further exacerbate these challenges, limiting investor confidence in the company's future financial performance.
This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction
Start investing in Abeona Therapeutics (ABEO)
Order type
Buy in
Order amount
Est. shares
0 shares